Causal factors affecting gross motor function in children diagnosed with cerebral palsy

Bruce A MacWilliams; Sarada Prasad; Amy L Shuckra; Michael H Schwartz

doi:10.1371/journal.pone.0270121

. 2022 Jul 18;17(7):e0270121. doi: 10.1371/journal.pone.0270121

Causal factors affecting gross motor function in children diagnosed with cerebral palsy

Bruce A MacWilliams ^1,^2,^*, Sarada Prasad ¹, Amy L Shuckra ¹, Michael H Schwartz ^3,⁴

Editor: YunJu Lee⁵

PMCID: PMC9292109 PMID: 35849563

Abstract

Background

Cerebral palsy (CP) is a complex neuromuscular condition that may negatively influence gross motor function. Children diagnosed with CP often exhibit spasticity, weakness, reduced motor control, contracture, and bony malalignment. Despite many previous association studies, the causal impact of these impairments on motor function is unknown.

Aim

In this study, we proposed a causal model which estimated the effects of common impairments on motor function in children with spastic CP as measured by the 66-item Gross Motor Function Measure (GMFM-66). We estimated both direct and total effect sizes of all included variables using linear regression based on covariate adjustment sets implied by the minimally sufficient adjustment sets. In addition, we estimated bivariate effect sizes of all measures for comparison.

Method

We retrospectively evaluated 300 consecutive subjects with spastic cerebral palsy who underwent routine clinical gait analysis. Model data included standard information collected during this analysis.

Results

The largest causal effect sizes, as measured by standardized regression coefficients, were found for selective voluntary motor control and dynamic motor control, followed by strength, then gait deviations. In contrast, common treatment targets, such as spasticity and orthopedic deformity, had relatively small effects. Effect sizes estimated from bivariate models, which cannot appropriately adjust for other causal factors, substantially overestimated the total effect of spasticity, strength, and orthopedic deformity.

Interpretation

Understanding the effects of impairments on gross motor function will allow clinicians to direct treatments at those impairments with the greatest potential to influence gross motor function and provide realistic expectations of the anticipated changes.

Introduction

Gross motor function in cerebral palsy

Gross motor function in children directly influences quality of life indicators such as activity and participation [1–3]. Children diagnosed with cerebral palsy (CP) often have limitations in their gross motor abilities [4]. An important goal of treatment for these children is to optimize functional abilities. However, knowing what to treat is not obvious, since the causal link from neurological and musculoskeletal factors to gross motor skills is poorly understood.

Cerebral palsy is a complex neurological condition and the most common childhood motor disability with incidence ranging from 2–3.5 per 1000 children [5]. CP describes a group of permanent movement and posture disorders in which damage to the developing brain impairs motor control and may induce spasticity, leading to reduced strength and abnormal musculoskeletal loading, in turn leading to joint contractures and bony deformities. Although the injury is non-progressive, secondary effects can continue to worsen with maturation. Function in this population is commonly measured using the Gross Motor Function Measure (GMFM), a task-based standardized test consisting of five domains that rate a patient’s level of function (A. Lying and Rolling, B. Sitting, C. Crawling and Kneeling, D. Standing, and E. Walking, Running and Jumping) [6]. The GMFM may be reported using the full 88-item score (GMFM-88), a 66-item score (GMFM-66) [7], or individual domain scores. The GMFM has been shown to be related to measures of mobility, self-care, and social function [8, 9]. For ambulatory children, the standing (GMFM-D) and walking, running, jumping (GMFM-E) domain scores are highly relevant to mobility.

Treatment options for children with CP span many disciplines including physical therapy, orthopaedic surgery, neurology, and physiatry. Physical therapy treatment focuses on goal oriented task to improve function and participation with interventions typically focused on strengthening, goal directed functional training, treadmill training, casting and bracing. Surgical treatment to address structural changes secondary to motor disorders commonly include lengthening of musculotendon units to improve range of motion, and osteotomy or guided growth to improve alignments. Multiple procedures are commonly performed at one surgical event, deemed single event multilevel surgery or SEMLS. Spasticity management may be attempted with either focal (chemodenervation) or global (baclofen, selective dorsal rhizotomy) approaches [10].

There is little evidence that any of these common treatments for the CP child improve function. Significant improvements in gross motor function have not been found with SEMLS [11–13]. Selective dorsal rhizotomy may result in small functional increases at short- and mid-term, but these are not maintained at long term follow-up [14–19]. Likewise, evidence of functional gains from physical therapy treatments are limited to short-term changes [20–22]. Knowing the relative influences of impairments on gross motor function can allow clinicians to target treatments at those impairments with the greatest impact on this important outcome domain.

Association studies of function

Much of the literature investigating the relationships between impairments and function consists of studies that consider the associations of a few chosen variables (e.g., strength of a single joint). Several such studies investigated relationships between impairments and gross motor function using bivariate correlation or regression; analysis of one independent variable of cause (e.g., spasticity, strength) to one dependent variable of effect (e.g., gait, GMFM) [23–26]. This approach is insufficient when complex relationships between variables exist, since it ignores the dependent effects of other influential variables. These studies focus on associations, with little or no formal discussion of causal mechanisms. For example, Shin et al. evaluated bivariate correlations between isometric hip and knee strength in 24 pediatric subjects with CP and GMFM-D, and GMFM-E. Correlations with GMFM domain scores ranged from r = 0.06–0.30, and none were significant. Other primary (e.g., motor control) and secondary (e.g., contracture) impairments were not considered, and each strength measure was considered in isolation [25].

When multivariate relationships have been explored, it has been done with limited variable sets, small numbers of participants, and without explicitly proposing and testing causal relationships. As an example, Eek and Beckung examined the relationships between hip, knee, and ankle strength and function in 55 children with CP. No other variables were considered. In contrast to Shin, significant bivariate correlations were found ranging from r = 0.59–0.80 between strength and GMFM-66. The multivariate combination most strongly correlated to GMFM-66 was ankle plantarflexor and hip flexor strength, yielding an r² = 0.73 [27].

While previous studies identified many factors associated with gross motor function, the utility of these models for guiding intervention is limited since pernicious effects like confounding, mediation, and opening of non-causal pathways is possible [28]. By analyzing strength in isolation, without consideration for the causal influences of other variables, Eek and Beckung’s results suggest that just two muscle groups account for 73% of the variance in GMFM-66. On the surface, these results imply strengthening these two muscles would be a highly effective therapy. However, neurological impairments do not occur in isolation. If weakness is influenced by poor motor control, age, or overall severity of injury, the effects of strengthening might be smaller than expected. In what follows we show that proper accounting for covariates reduces the apparent importance implied by non-causal analysis of many individual clinical factors.

Explicit causal approach

Behind most, if not all, association studies lurks an implicit causal hypothesis. It is unlikely that Eek and Beckung were simply trying to demonstrate an association between strength and GMFM-66. Rather, their study almost certainly reflects an assumption that strength is an important cause of function. We demonstrate below that strength is an important causal factor, though with a substantially smaller impact than bivariate estimates would suggest. However, if causal claims are going to be made, they should be explicit and they should be tested.

An explicit causal model provides a set of conditions that assess the plausibility of the model. Once plausibility is established, a casual model can be used to derive covariate adjustments necessary for statistical modeling. Both the direct effect sizes (dependent variable changes occurring from isolated independent variable changes) and total effect sizes (dependent variable changes occurring when the independent variable is transmitted through mediator variables) can be evaluated to assess the relative influences of model variables [29]. There has been limited use of causal modeling in the study of CP. Kim and Park proposed a simple causal model to examine the effects of spasticity and strength on GMFM-88 and functional outcomes as measured by the Pediatric Evaluation of Disability Inventory (PEDI) [30]. Only GMFM-88 had significant direct effects on PEDI, whereas spasticity and strength had indirect effects, mediated by GMFM-88. The authors noted that the model lacked other potentially important variables such as orthopedic deformities.

Instrumented three-dimensional gait analysis is a common diagnostic and treatment-planning tool used in the assessment of children with CP. Standard gait analysis protocols include direct and indirect measures of neurological and orthopedic impairments that may influence function. The aim of this study is to hypothesize and test a causal model for GMFM-66 that examines the influence of key neurological and orthopedic impairments commonly measured during a gait analysis visit, which includes a comprehensive physical exam, standard functional measures, and 3D kinematics and electromyography collected during walking. Compared to Kim and Park’s study, our proposed model considers measures encompassing all International Classification of Functioning, Disability and Health (ICF, www.asha.org/slp/icf) domains, including measures of orthopedic deformity, spasticity, gait quality, and both dynamic and selective motor control. Understanding the causal factors influencing function can help to better educate patients, families, and providers about realistic goals for treatments.

Methods

Approval with a waiver of informed consent was obtained for this retrospective analysis through the Western IRB (study number 1249365).

Causal model

A graphical causal model [31, 32] is proposed to explain how a set of commonly measured and potentially treatable neurological and orthopedic impairments affect function as measured by GMFM-66 (Fig 1 and Table 1). Model inputs are limited to those variables routinely collected during a motion analysis study for children with spastic CP at one center. The hypothesized relationships in the model, along with linearity assumptions, lead to conditional independence tests that assess the plausibility of the model and covariate adjustment sets for statistical models used to estimate the relative causal contributions of various factors [28].

Fig 1 — Alternatively called a causal Bayesian network. Representation of the causal model where arrows indicate hypothesized cause (tail) and effect (head) relationships. See Table 1 for hypothesized relationships of variables included.

Table 1. Causal model.

Clinical Feature	Measure	Causes
Injury
Age	Age
Motor Control	MC, Latent	Injury
Selective Motor Control	SCALE	Motor Control, Age
Dynamic Motor Control	DMC	Motor Control, Age
Strength^a	Strength	Injury, Motor Control, Age
Spasticity	Spasticity	Injury, Age
Contracture	Latent
Ankle Dorsiflexion Contracture^b	AnkleDF	Strength, Spasticity, Dynamic & Selective voluntary motor control, Age
Knee Extension Contracture^b	KneeExt	Strength, Spasticity, Dynamic & Selective voluntary motor control, Age
Hamstrings Contracture^b	Popliteal	Strength, Spasticity, Dynamic & Selective voluntary motor control, Age
Hip Extension Contracture^b	HipExt	Strength, Spasticity, Dynamic & Selective voluntary motor control, Age
Torsion	Latent
Tibial Torsion^c	TibRot	Strength, Spasticity, Dynamic & Selective voluntary motor control, Age
Femoral Anteversion^c	FemRot	Strength, Spasticity, Dynamic & Selective voluntary motor control, Age
Gait Pattern	GDI	Strength, Spasticity, Dynamic & Selective voluntary motor control, Age, Ankle ROM, Knee ROM, Popliteal ROM, Hip ROM, Tibial Torsion, Femoral Anteversion
Gross Motor Function	GMFM-66	Strength, Spasticity, Dynamic & Selective voluntary motor control, Age, Ankle ROM, Knee ROM, Popliteal ROM, Hip ROM, Gait Pattern

Open in a new tab

Features included in the causal model illustrated in Fig 1. Measures here match the Fig 1 variable names. The hypothesized direct causes of each feature are listed.

a. Because we measure strength in an age-adjusted manner, we do not include an explicit causal link in our graphical model used for testing plausibility and determining adjustment sets.

b. Ankle, Knee, Hamstrings, and Hip contractures are influenced by an unmeasured latent variable Contracture so that Contracture → Ankle Dorsiflexion Contracture, Contracture → Knee Extension Contracture, Contracture → Hamstrings Contracture, Contracture → Hip Extension Contracture.

c. Tibial Torsion and Femoral Anteversion are influenced by an unmeasured latent variable Torsion so that T → Tibial Torsion, T → Femoral Anteversion.

The model is developed by considering the included clinically relevant variables and forming a hypothesis of how each variable influences every other variable in a causal relationship. If there is reasonable evidence or if a logical inference of direct causality exists, then graphically, a linkage is added from the causal variable to the effected variable. If a causal variable’s effect is fully mediated by other included variables, then a direct effect is not included. The causal model proposed here starts with the neurologic injury that has led to the diagnosis of CP. The primary impairments resulting from this injury commonly manifest as spasticity and reductions in selective motor control, dynamic motor control, and strength. Each of these neurological factors is hypothesized to have a direct effect on gross motor function. Additionally, these primary impairments cause gait deviations through improper muscle activation patterns, which in turn impairs GMFM-66 by making intended movements more difficult. Selective voluntary motor control deficits also reduce strength by impeding the ability to isolate and volitionally activate muscles, resulting in functional weakness. Strength in turn affects both gait and gross motor function by altering and limiting movement strategies. The effect of age on gross motor function is accounted for both directly, reflecting motor learning associated with practice, and indirectly, reflecting neuromaturation and growth. Orthopedic deformities, in the form of contractures (Ankle, Knee, Hamstrings, and Hip) are caused, in part, by the improper muscle forces brought about by spasticity, poor strength, and poor motor control. These improper forces also influence the remodeling of bony torsions (femoral anteversion and tibial torsion). Contractures and long-bone torsions both affect gait, and the contractures directly impede gross motor function by restricting movement. Note that we assume no direct effect of long bone torsion on gross motor function. There are undoubtedly other impairments associated with the injury that are not represented. For the present model, these other factors are ignored. This meaningful limitation and its impact on our results will be discussed later.

Study data

We evaluated the model using 300 consecutive unique individuals with a diagnosis of CP who were seen at a single center for a quantitative 3D gait assessment including electromyography (EMG) of the lower extremity and had complete datasets. All studies were conducted by an experienced physical therapist. The center collecting the data was fully accredited during the times of data collection (Center for Motion Laboratory Accreditation, cmlainc.org). For all bilateral measures, averages between sides were used, including for unilaterally involved individuals. The following metrics categorized by ICF domains were used for the model.

Body functions and structure

Spasticity was computed on a 0–5 scale derived from multiple measures collected during physical examination [33]. The spasticity scale included modified Ashworth scales [34] recorded for between 3 to 5 muscles, Duncan-Ely tests of rectus femoris spasticity, beats of clonus, and ankle plantarflexor differences between initial catch of quick stretch and maximal values [33].

Strength was measured by both manual muscle testing grade and hand-held dynamometry of lower extremity muscle groups. Dynamometry values were expressed as z-scores relative to typically developing individuals after controlling for gender, age, and height [35, 36]. These were then combined with manual grades to yield a composite 0–5 strength scale.

Selective motor control was measured using the Selective Control Assessment of the Lower Extremity (SCALE). Total limb SCALE values (0–10 scale) were used as an overall representation of selective motor control [37].

Limb rotational deformities were measured with an inclinometer. Femoral anteversion was estimated from the midpoint between maximum inward and outward rotation of the hip with the subject prone and knee flexed to 90° [38]. Tibial torsion was estimated using bimalleolar and epicondyle landmarks with the subject supine and the knee extended [39, 40]. Typically developing values of 26.9° for femoral anteversion and 16.0° for tibial torsion were subtracted from raw data to reflect deviations from typical developing norms, with positive values internally directed [41].

Sagittal plane joint end ranges of motion were measured with handheld goniometry. Maximal hip extension was measured with the opposite hip flexed, knee extension in a supine position, popliteal angle with the opposite leg extended, and ankle dorsiflexion in a prone position with the knee at maximal extension [39, 40]. Joint contractures were expressed as the measured raw end range values offset by reported typically developing values: 0° for hip extension contracture, 4° of hyperextension (recurvatum) for knee extension contracture, 25.6° popliteal angle for hamstrings contracture, and 21.3° for ankle dorsiflexion contracture [41].

Activity and participation

Gait quality was measured by the gait deviation index (GDI), computed using published techniques [42]. The GDI is a validated measure of overall gait deviations, scaled so that 100 (10) is the mean (sd) for typically developing controls.

Dynamic motor control was expressed by the Walking Dynamic Motor Control Index (Walk-DMC), calculated from electromyography collected during walking at self-selected speed. Walk-DMC is a validated measure of motor control that is scaled so that 100 (10) is the mean (standard deviation) of typically developing peers. Walk-DMC values were computed based on the methods described by Steele et al. [43], using an aggregate analysis of 5–7 self-selected speed trials obtained as part of the clinical gait analysis protocol.

Gross motor function classification level (GMFCS) and the 66 item gross motor function measure (GMFM-66) were recorded by the physical therapist conducting the examination.

Personal factors

Age at assessment was considered to reflect maturation of strength and control. Height, weight, and gender were recorded and used to normalize dynamometry strength measures, but otherwise were not hypothesized to be explicit causal factors in this analysis.

Health condition

CP subtype (hemiplegia, diplegia, quadriplegia) was determined from the medical record.

Variables were transformed as follows. First, each variable was standardized using the sample mean and standard deviation. Next, the sign of the variable was adjusted so that larger values indicate less impairment and smaller values indicate more impairment. This was done so that positive effect sizes imply a higher score (better function) on the GMFM-66 scale. For age, larger values retain the conventional meaning of older.

Analysis

Implied conditional independencies were identified to test the plausibility of the proposed model [31]. These conditional independencies are a list of partial correlations that must be zero or insignificant for the observed data to be consistent with the structure of the hypothesized causal model [44]. Meeting these conditions is necessary, but not sufficient, for a causal model to be correct, since there can be multiple models that meet the same implied independencies.

We chose to use linear models to estimate the magnitude and sign of total and direct causal effects for each factor of interest. A linear model was built for each factor whose effect size was being investigated using the adjustment set identified from the causal model. Adjustment sets are lists of covariates that, when included in the linear model, allow the causal effect of a particular factor to be estimated by controlling appropriately for other factors. Only main effects were allowed in the linear models (no interactions). This decision was driven by both causal and practical considerations. From a causal perspective, we did not see clear rationale for interaction effects, and, if they did exist, we assumed they would likely be substantially smaller than the main effects. From a practical perspective, we know that spurious significant interactions are likely, given the number of factors under consideration, and that approximately 16x more samples are needed to detect significant interactions compared to main effects [45]. Thus, in light of our relatively coarse measurements and modest sample size, we settled on a main-effects-only model. In addition to deriving causal effect sizes for each individual factor, we also built a predictive model to examine the total causal effect of the factors taken together, enabling estimates of GMFM-66 as a function of the key clinical measures of neurological and orthopedic impairment.

We also derived bivariate linear models to assess the apparent, non-causal, effect sizes for each of the factors considered in the causal model. For example, we regressed GMFM-66 against Strength as a single predictor, then against Spasticity as a single predictor, and so on. The effect sizes from the bivariate models typify the estimates that result from the non-causal association analyses that pervade the literature. Thus, comparing the causal and bivariate results shows the interpretive errors that can arise from using a non-causal method.

A 10-fold cross-validation was performed to estimate the model’s performance on out-of-sample observations, thereby quantifying the ability of model to predict GMFM-66. All modeling and statistics were performed with R (version 4.02, R Core Team, 2020). Causal model building and testing was done using dagitty [31].

Results

Participants were typical for the population of CP patients referred for clinical gait analysis at our center (Table 2). We screened 314 individuals to reach the final cohort of 300 participants. Three subjects excluded had missing data due to visit time constraints while the other 11 were unable to complete testing due to an inability to follow directions. Of these 11, five were age six years or younger.

Table 2. Participant characteristics.

Variable	Units	TD Value	GMFCS I	GMFCS II	GMFCS III
mean (SD) unless noted	Units	TD Value	GMFCS I	GMFCS II	GMFCS III
Number of Participants			115	132	53
CP Subtype (%)
Spastic diparesis			30 (26)	95 (72)	47 (89)
Spastic hemiparesis			86 (74)	32 (24)	0 (0)
Spastic quadriparesis			0 (0)	5 (4)	6 (11)
Gender = Male (%)			52 (45)	75 (57)	34 (64)
Age	Yr.		10.5 (3.5)	11.6 (3.5)	10.9 (3.3)
Walk-DMC	None	100	91 (10.0)	80 (12.2)	66 (9.8)
GDI	None	100	82 (10.7)	71 (9.4)	63 (8.5)
SCALE	None	10	6.8 (1.4)	5.2 (1.4)	3.0 (1.4)
Spasticity	None	1	1.6 (0.9)	2.1 (1.1)	2.9 (1.1)
Strength	None	5	4.6 (0.3)	4.2 (0.5)	3.5 (0.6)
GMFM-66	None	100	87 (6.2)	73 (7.0)	57 (4.6)
Ankle Dorsiflexion Contracture	Deg.	0	-17 (6.1)	-20 (8.1)	-20 (8.2)
Knee Extension Contracture	Deg.	0	1 (4.9)	-2 (7.2)	-7 (8.8)
Hamstrings Contracture	Deg.	0	-13 (17.4)	-24 (18.7)	-31 (18.3)
Hip Extension Contracture	Deg.	0	-1 (2.7)	-4 (5.1)	-8 (7.6
Femoral Anteversion Deviation	Deg.	0	-1 (24.1)	-4 (25.7)	-11 (24.9)
Tibial Torsion Deviation	Deg.	0	-1 (5.8)	-2 (6.7)	-3 (7.0)

Open in a new tab

Note: Raw values reported. Contractures are negative values. For femoral anteversion and tibial torsion, positive values are inwardly directed. For modeling purposes, variables were transformed so that more positive values indicated less impairment and more negative values indicated more impairment.

Standardized coefficients were computed to assess effect sizes for the various neurological and orthopedic factors (Fig 2). Comparing effect sizes between the causal model and the bivariate regression models shows the important impact that causal modeling can have on effect sizes. Bivariate (non-causal) effect sizes overestimated the importance of factors by 0.18–0.48 compared to their causal counterparts, which corresponded to bivariate overestimations of more than double at a minimum to several fold.

All but two of the 11 independencies implied by the structure of our proposed causal model were statistically insignificant (no adjustment for multiple comparisons). There were significant correlations between hip extension contracture and tibial torsion (r = .18) and knee extension contracture and tibial torsion (r = .28), both conditional on age, DMC, SCALE, spasticity, and strength. This result demonstrates that the structure of the proposed causal model is largely consistent with the observed data, suggesting that the proposed model is plausible.

Coefficients for the direct linear model were estimated for all causal factors (Table 3). The cross validation analysis resulted in an out-of-sample r² = 0.75 and a mean absolute error of 4.9 points (Fig 3).

Table 3. Predictive model coefficients.

Variable	β	SE	p	Units	Range	TD	Description
Intercept	14.7	4.3	< .01	S	NA	NA	GMFM-66 linear intercept [7]
Age	0.08	0.12	.50	Yr.	NA	NA	Child’s age in decimal years (e.g. 10.4 yrs)
SCALE	2.3	.27	< .01	S	0–10	10	SCALE total limb score bilateral average (0–10) [37]
Walk-DMC	0.24	0.04	< .01	S	22–100+*	100 (10)	Dynamic motor control scaled from normal [43]
Strength	4.5	0.85	< .01	S	0–5	5	Multivariate strength scale [35]
Spasticity	-0.57	0.38	.13	S	0–5	0	Multivariate spasticity scale [33]
GDI	0.17	0.04	< .01	S	0–100+*	100 (10)	Gait deviation index [42]
Ankle Dors. Contracture	-0.13	0.05	< .01	Deg.	> = 0	0	Limitation in achieving > = 21.3° dorsiflexion with knee extended [39–41]
Hip Ext. Contracture	-0.17	0.08	.02	Deg.	> = 0	0	Limitation in achieving > = neutral hip extension [39, 40]
Knee Ext. Contracture	-0.11	0.07	.10	Deg.	> = 0	0	Limitation in achieving > = 4.0° knee extension with hip at neutral [39–41]
Hamstrings Contracture	-0.01	0.02	.54	Deg.	> = 0	0	Limitation in achieving > = 25.6° knee extension with hip flexed to 90° (Popliteal Angle) [39–41]
Femoral Anteversion	-0.01	0.02	.44	Deg.	> = 0	0	Difference from typical anteversion (26.9°) [38, 41]
Tibial Torsion	-0.08	0.08	.21	Deg.	> = 0	0	Non-weightbearing bimalleolar axis difference from typical (16.0°) [39–41]

Open in a new tab

S = unitless scale variable defined in description.

NA = not applicable, TD = typically developing value, SE = standard error, p = p-value.

*Both Walk-DMC and GDI are scaled Z-scores that can exceed the mean typical value of 100, additionally Walk-DMC has a theoretical minimum value dependent upon the scaling values.

To obtain subject GMFM66 use equation: GMFM66 = Intercept + ∑_iβ_i ∙ Variable_i.

Fig 3 — Data from a 10-fold cross validation of the final total effects linear model. The diagonal line indicates perfect agreement. The cross-validated r² = 0.75 and mean absolute error = 4.9 points.

Discussion

A causal model of function in children with CP provided estimates of direct and total effect sizes for key clinical impairments, and explained 75% of the variance in the GMFM-66 scores in an out-of-sample test set (10-fold cross-validation). The model is plausible and can be evaluated using measurements collected during routine gait analysis evaluations. Selective voluntary motor control, dynamic motor control, and strength had the largest total effects on GMFM-66. Gait impairments (GDI) had the next largest impact on GMFM-66. Note that GDI is not directly manipulable by treatment, but rather it changes in response to modification of orthopedic or neurological factors. Ankle and hip contractures had small effects on GMFM-66, while other orthopedic deformities had statistically insignificant effects. The causal effects of most factors were found to be substantially smaller than those obtained from bivariate analysis.

Our findings have important clinical implications. First, the effects of these measures on gross motor function can guide targets for treatment and inform expectations regarding possible improvements. Second, the results indicate that 75% of gross motor function as measured by the GMFM-66 can be accounted for by measures commonly recorded during clinical gait analysis. Finally, the results clearly show the errors that can arise from computing non-causal, bivariate relationships among clinical factors in children diagnosed with CP. The interconnectedness of neurological and musculoskeletal impairments, gait, and function in this population places a premium on employing analyses that respect the complexity of the clinical condition.

Selective voluntary motor control, as measured by the SCALE composite limb score, had the highest effect in the total effects model. The SCALE score has previously been associated with GMFM-66, and our analysis confirms that this association appears to be causal [46]. Dynamic motor control, as measured by Walk-DMC [43], also had a large effect size, even after controlling for selective voluntary motor control. This suggests that the neurological pathways employed during quasi-static tasks and those used during gait are not the same, and both are important for function. In our proposed model, selective and dynamic motor control deficits share a common cause and are hence correlated (Walk-DMC ← Injury → SCALE). Walk-DMC has previously been associated with changes in gait measures after treatment, including overall gait deviation (GDI), consistent with the proposed causal diagram (Fig 1) in this study [47]. The same study demonstrated that Walk-DMC was associated with changes in the sports and physical function sub-score of the pediatric outcomes data collection instrument (PODCI). While the PODCI sports and physical function score is not identical to the GMFM-66, it is reasonable to think that there is a significant overlap in the underlying construct of the two measures. Selective and dynamic motor control and are difficult to alter with treatments or therapies. Nevertheless, our results suggest that we should continue efforts towards finding control-enhancing therapies, as these hold the greatest prospect for impacting overall function.

Spasticity is another common primary neurological impairment observed in children diagnosed with CP. Both the direct and total effects of spasticity were shown to be relatively small. Thus, intrathecal baclofen pump implantation, selective dorsal rhizotomy, or chemodenervation therapies aimed at spasticity reduction should not be expected to appreciably improve gross motor function. This prediction is consistent with what has been observed in outcome analyses of these treatments [16, 48, 49].

Age did not have a significant effect. Thus, independent of neurological and orthopedic impairments, age alone is not expected to alter gross motor function substantially. Contradicting this finding is previous work showing that GMFM-66 improves from an early age and begins to plateau around age 8 [50]. Approximately 85% of the individuals in this study were older than 7.5, and this may explain our finding that age was not an important cause of GMFM-66. In addition, the largest improvements due to ageing are observed in Gross Motor Function Classification (GMFCS) I individuals [51], who make up only 38% of our study population. Furthermore, we made the simplifying assumption of linearity, which cannot accurately model the growth and plateauing nature of previously observed GMFM-66 vs. age response. Lastly, the well-known GMFM-66 vs. age curves are stratified by GMFCS. While GMFCS may constitute a reasonable adjustment set, our causal model would suggest the nature of GMFM-66 changes are more complex. In fact, GMFCS level can be thought of as a causal consequence of many factors in our model. Put another way, children with poorer strength and motor control and worse spasticity are likely to be classified with a GMFCS level indicating greater severity of the disease. Thus, adjusting for GMFCS alone may not fully capture the effects that motor control, strength, orthopedic impairments, and gait impairments have on function. The lack of a direct age effect in our model suggests that changes in other factors with age (e.g. contractures, strength, gait quality) may explain some of the marginal age effect observed in the GMFM-66.

The effect sizes of strength and gait quality (GDI) were both significant, suggesting that they are important causes of function. Both variables can be improved by treatment (strengthening, physical therapy, orthopedic surgery). While our model suggests that improvement in these domains can raise gross motor function, the evidence for this in practice is not clear. Outcomes of these therapies have not consistently demonstrated improved function in patients [52]. One possible explanation could be the magnitude of strength or GDI improvement achieved with treatment. The standardized effect size for strength and GDI are 0.26 and 0.16, respectively. This means that for one standard deviation of strength improvement, we should expect 0.26 standard deviations of GMFM-66 improvement (3.2 points for the data in this study), and for one standard deviation of GDI improvement we should expect 0.16 standard deviations in GMFM-66 improvement (2.0 points). Typical GDI improvements following surgery are on the order of 7 points, which would correspond to ~1.3 point improvement on GMFM-66 scores, well below the reported minimally clinical important difference [53].

Similar to Kim and Park’s less comprehensive causal model of function [30], we found that both spasticity and strength had significant effects on GMFM-66. However, the inclusion of additional causal factors significantly changed the absolute and relative magnitude of the effect sizes. Kim and Park estimated the effect sizes for spasticity and strength to be 0.34 and 0.45, respectively, while we found them to be 0.08 and 0.26. Differences in testing methods for these subjective measures may impact absolute effect sizes, but should have less impact on relative effect sizes, which were also substantially different in our model compared to Kim and Park’s (4.82 and 3.25, respectively).

One limitation to this study was the exclusion of 14 individuals (4%) due to missing data. In some cases, data was not collected due to the patient’s inability to follow instructions. These missing data have potential to bias the results since some of the lowest functioning individuals may have been excluded. However, only six subjects (2%) were excluded for this reason. In addition, both sides of bilateral measures for unilateral individuals were included and averaged. While this may diminish the influence of the condition on the hemiparetic side, GMFM-66 is a score for an individual, allowing compensatory contributions of the non-hemiparetic side, and thus we reasoned that averaging sides was an appropriate approach. Finally, this is a retrospective analysis of cross sectional data and all causal relationships are hypothesized based on past observations or logistically based assumptions.

Summary

A causal diagram is a hypothesis. Since counterfactual observations (e.g., a clone of a specific child with one clinical parameter altered) do not exist, causal diagrams can never be fully proven or falsified. They can, however, be tested for plausibility from both a domain knowledge and statistical perspective. We showed that the proposed diagram is plausible and explained 75% of the variance in GMFM-66. Nevertheless, unobserved and unmeasured variables may play a significant role. As data were limited to variables retrospectively collected from standard gait analysis studies at a single center, some potentially important factors were omitted. Cognition may be one such omitted but important variable [54]. It is likely that cognition plays a meaningful role in function and including this variable could change the effect sizes of the factors we have examined. Socio-economic factors, access to resources, participation in the community, availability of recreational sports opportunities, emotional health, and myriad other complex factors could also be considered in future extensions of this model.

This study should be viewed as a starting point, and not as a definitive model of causality and function in children with CP. We proposed a model limited to data available from existing motion analysis studies, demonstrated its plausibility, and estimated the causal effect sizes of key clinical factors. We also showed that important differences in interpretation arise when causality, rather than association, is considered. The strength of our approach is the explicit proposal of a causal diagram, leading to a priori statistical models. This contrasts with much of the previous work in this area, which commonly examines ad hoc bivariate relationships in an unstructured methodology. In many cases, the bivariate approach leads to significant and strong correlations, but these findings may be misleading since they lack the proper causal context.

As noted earlier, lurking behind virtually every study of association is a hidden belief in a causal relationship. Except for purely predictive models, we suspect no researchers examine associations without some underlying hypothesis about causality. While our proposed model is imperfect, it is transparent and explicit. Additional work is needed to discover more complete causal models and to devise experiments that confirm or refute the results of these models. The complexity of CP and the relationships among commonly measured variables demand that causality be considered when interpreting data.

Conclusions

Our model results highlight the challenges faced for improving function in children with CP. The largest effect sizes are found in the selective and dynamic motor control measures; impairments for which there are currently no highly effective treatments. In contrast, spasticity, which we can treat via rhizotomy or baclofen pump, has a very small impact on gross motor function. Strength and gait quality both have significant, but modest, effect sizes. However, improvements in these domains following treatment tend to be small, leading to minimal functional gains. If we hope to improve function through these domains, we need more effective treatments for strength and gait.

Supporting information

S1 Data

(CSV)

Click here for additional data file.^{(42.7KB, csv)}

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

The author(s) received no specific funding for this work.

References

1.Kerr C, McDowell B, McDonough S. The relationship between gross motor function and participation restriction in children with cerebral palsy: an exploratory analysis. Child: Care, Health and Development. 2007;33: 22–27. doi: 10.1111/j.1365-2214.2006.00634.x [DOI] [PubMed] [Google Scholar]
2.Lee B-H. Relationship between gross motor function and the function, activity and participation components of the International Classification of Functioning in children with spastic cerebral palsy. Journal of Physical Therapy Science. 2017;29: 1732–1736. doi: 10.1589/jpts.29.1732 [DOI] [PMC free article] [PubMed] [Google Scholar]
3.Palisano RJ, Kang L-J, Chiarello LA, Orlin M, Oeffinger D, Maggs J. Social and community participation of children and youth with cerebral palsy is associated with age and gross motor function classification. Physical Therapy. 2009;89: 1304–1314. doi: 10.2522/ptj.20090162 [DOI] [PubMed] [Google Scholar]
4.Rosenbaum PL, Walter SD, Hanna SE, Palisano RJ, Russell DJ, Raina P, et al. Prognosis for gross motor function in cerebral palsy: creation of motor development curves. JAMA. 2002;288: 1357–1363. doi: 10.1001/jama.288.11.1357 [DOI] [PubMed] [Google Scholar]
5.Colver A, Fairhurst C, Pharoah POD. Cerebral palsy. Lancet. 2013. doi: 10.1016/S0140-6736(13)61835-8 [DOI] [PubMed] [Google Scholar]
6.Russell DJ, Rosenbaum PL, Cadman DT, Gowland C, Hardy S, Jarvis S. The gross motor function measure: a means to evaluate the effects of physical therapy. Developmental Medicine and Child Neurology. 1989;31: 341–352. doi: 10.1111/j.1469-8749.1989.tb04003.x [DOI] [PubMed] [Google Scholar]
7.Russell DJ, Avery LM, Rosenbaum PL, Raina PS, Walter SD, Palisano RJ. Improved scaling of the gross motor function measure for children with cerebral palsy: evidence of reliability and validity. Phys Ther. 2000;80: 873–885. [PubMed] [Google Scholar]
8.Ostensjø S, Carlberg EB, Vøllestad NK. Motor impairments in young children with cerebral palsy: relationship to gross motor function and everyday activities. Dev Med Child Neurol. 2004;46: 580–589. doi: 10.1017/s0012162204000994 [DOI] [PubMed] [Google Scholar]
9.Smits D-W, Gorter JW, Ketelaar M, Van Schie PE, Dallmeijer AJ, Lindeman E, et al. Relationship between gross motor capacity and daily-life mobility in children with cerebral palsy. Dev Med Child Neurol. 2010;52: e60–66. doi: 10.1111/j.1469-8749.2009.03525.x [DOI] [PubMed] [Google Scholar]
10.Novak I, McIntyre S, Morgan C, Campbell L, Dark L, Morton N, et al. A systematic review of interventions for children with cerebral palsy: state of the evidence. Dev Med Child Neurol. 2013;55: 885–910. doi: 10.1111/dmcn.12246 [DOI] [PubMed] [Google Scholar]
11.Thomason P, Baker R, Dodd K, Taylor N, Selber P, Wolfe R, et al. Single-event multilevel surgery in children with spastic diplegia: a pilot randomized controlled trial. The Journal of Bone and Joint Surgery American Volume. 2011;93: 451–460. doi: 10.2106/JBJS.J.00410 [DOI] [PubMed] [Google Scholar]
12.McGinley JL, Dobson F, Ganeshalingam R, Shore BJ, Rutz E, Graham HK. Single-event multilevel surgery for children with cerebral palsy: a systematic review. Developmental Medicine and Child Neurology. 2012;54: 117–128. doi: 10.1111/j.1469-8749.2011.04143.x [DOI] [PubMed] [Google Scholar]
13.Chang C-H, Chen Y-Y, Yeh K-K, Chen C-L. Gross motor function change after multilevel soft tissue release in children with cerebral palsy. Biomedical Journal. 2017;40: 163–168. doi: 10.1016/j.bj.2016.12.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
14.Bolster EAM, van Schie PEM, Becher JG, van Ouwerkerk WJR, Strijers RLM, Vermeulen RJ. Long-term effect of selective dorsal rhizotomy on gross motor function in ambulant children with spastic bilateral cerebral palsy, compared with reference centiles. Developmental Medicine and Child Neurology. 2013;55: 610–616. doi: 10.1111/dmcn.12148 [DOI] [PubMed] [Google Scholar]
15.van Schie PEM, Schothorst M, Dallmeijer AJ, Vermeulen RJ, van Ouwerkerk WJR, Strijers RLM, et al. Short- and long-term effects of selective dorsal rhizotomy on gross motor function in ambulatory children with spastic diplegia. Journal of Neurosurgery Pediatrics. 2011;7: 557–562. doi: 10.3171/2011.2.PEDS10452 [DOI] [PubMed] [Google Scholar]
16.Tedroff K, Hägglund G, Miller F. Long-term effects of selective dorsal rhizotomy in children with cerebral palsy: a systematic review. Developmental Medicine and Child Neurology. 2020;62: 554–562. doi: 10.1111/dmcn.14320 [DOI] [PMC free article] [PubMed] [Google Scholar]
17.Tedroff K, Löwing K, Åström E. A prospective cohort study investigating gross motor function, pain, and health-related quality of life 17 years after selective dorsal rhizotomy in cerebral palsy. Developmental Medicine and Child Neurology. 2015;57: 484–490. doi: 10.1111/dmcn.12665 [DOI] [PubMed] [Google Scholar]
18.McLaughlin J, Bjornson K, Temkin N, Steinbok P, Wright V, Reiner A, et al. Selective dorsal rhizotomy: meta-analysis of three randomized controlled trials. Developmental Medicine and Child Neurology. 2002;44: 17–25. doi: 10.1017/s0012162201001608 [DOI] [PubMed] [Google Scholar]
19.MacWilliams BA, McMulkin ML, Duffy EA, Munger ME, Chen BP-J, Novacheck TF, et al. Long-term effects of spasticity treatment, including selective dorsal rhizotomy, for individuals with cerebral palsy. Developmental Medicine & Child Neurology. 2021; n/a. doi: 10.1111/dmcn.15075 [DOI] [PubMed] [Google Scholar]
20.Tsorlakis N, Evaggelinou C, Grouios G, Tsorbatzoudis C. Effect of intensive neurodevelopmental treatment in gross motor function of children with cerebral palsy. Developmental Medicine and Child Neurology. 2004;46: 740–745. doi: 10.1017/s0012162204001276 [DOI] [PubMed] [Google Scholar]
21.İçağasıoğlu A, Mesci E, Yumusakhuylu Y, Turgut ST, Murat S. Rehabilitation outcomes in children with cerebral palsy during a 2 year period. Journal of Physical Therapy Science. 2015;27: 3211–3214. doi: 10.1589/jpts.27.3211 [DOI] [PMC free article] [PubMed] [Google Scholar]
22.Park E-Y. Effect of physical therapy frequency on gross motor function in children with cerebral palsy. Journal of Physical Therapy Science. 2016;28: 1888–1891. doi: 10.1589/jpts.28.1888 [DOI] [PMC free article] [PubMed] [Google Scholar]
23.Kramer JF, MacPhail AH. Relationships Among Measures of Walking Efficiency, Gross Motor Ability, and Isokinetic Strength In Adolescents With Cerebral Palsy. Pediatric Physical Therapy. 1994;6: 3–9. [Google Scholar]
24.Damiano DL, Martellotta TL, Sullivan DJ, Granata KP, Abel MF. Muscle force production and functional performance in spastic cerebral palsy: relationship of cocontraction. Arch Phys Med Rehabil. 2000;81: 895–900. doi: 10.1053/apmr.2000.5579 [DOI] [PubMed] [Google Scholar]
25.Shin HI, Sung KH, Chung CY, Lee KM, Lee SY, Lee IH, et al. Relationships between Isometric Muscle Strength, Gait Parameters, and Gross Motor Function Measure in Patients with Cerebral Palsy. Yonsei Med J. 2016;57: 217–224. doi: 10.3349/ymj.2016.57.1.217 [DOI] [PMC free article] [PubMed] [Google Scholar]
26.Ross SA, Engsberg JR. Relationships Between Spasticity, Strength, Gait, and the GMFM-66 in Persons With Spastic Diplegia Cerebral Palsy. Archives of Physical Medicine and Rehabilitation. 2007;88: 1114–1120. doi: 10.1016/j.apmr.2007.06.011 [DOI] [PubMed] [Google Scholar]
27.Eek MN, Beckung E. Walking ability is related to muscle strength in children with cerebral palsy. Gait Posture. 2008;28: 366–371. doi: 10.1016/j.gaitpost.2008.05.004 [DOI] [PubMed] [Google Scholar]
28.Pearl J. Causal diagrams for empirical research. Biometrika. 1995;82: 669–688. doi: 10.1093/biomet/82.4.669 [DOI] [Google Scholar]
29.Fairchild AJ, MacKinnon DP, Taborga MP, Taylor AB. R2 effect-size measures for mediation analysis. Behav Res Methods. 2009;41: 486–498. doi: 10.3758/BRM.41.2.486 [DOI] [PMC free article] [PubMed] [Google Scholar]
30.Kim WH, Park EY. Causal relation between spasticity, strength, gross motor function, and functional outcome in children with cerebral palsy: a path analysis. Developmental Medicine and Child Neurology. 2011;53: 68–73. doi: 10.1111/j.1469-8749.2010.03777.x [DOI] [PubMed] [Google Scholar]
31.Textor J, van der Zander B, Gilthorpe MS, Liśkiewicz M, Ellison GT. Robust causal inference using directed acyclic graphs: the R package ‘dagitty.’ Int J Epidemiol. 2016;45: 1887–1894. doi: 10.1093/ije/dyw341 [DOI] [PubMed] [Google Scholar]
32.Pearl J. Causality. 2nd ed. Cambridge: Cambridge University Press; 2009. doi: 10.1017/CBO9780511803161 [DOI] [Google Scholar]
33.Munger ME, Chen BP-J, MacWilliams BA, McMulkin ML, Schwartz MH. Comparing the effects of two spasticity management strategies on the long-term outcomes of individuals with bilateral spastic cerebral palsy: a multicentre cohort study protocol. BMJ open. 2019;9: e027486. doi: 10.1136/bmjopen-2018-027486 [DOI] [PMC free article] [PubMed] [Google Scholar]
34.Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Physical Therapy. 1987;67: 206–207. doi: 10.1093/ptj/67.2.206 [DOI] [PubMed] [Google Scholar]
35.Kendall FP. Muscles: Testing and function with posture and pain. Baltimore, MD: Lippincott Williams & Wilkins; 2005. [Google Scholar]
36.van der Ploeg RJ, Oosterhuis HJ. The “make/break test” as a diagnostic tool in functional weakness. Journal of Neurology, Neurosurgery, and Psychiatry. 1991;54: 248–251. doi: 10.1136/jnnp.54.3.248 [DOI] [PMC free article] [PubMed] [Google Scholar]
37.Fowler EG, Staudt LA, Greenberg MB, Oppenheim WL. Selective Control Assessment of the Lower Extremity (SCALE): development, validation, and interrater reliability of a clinical tool for patients with cerebral palsy. Dev Med Child Neurol. 2009;51: 607–614. doi: 10.1111/j.1469-8749.2008.03186.x [DOI] [PubMed] [Google Scholar]
38.Kerr AM, Kirtley SJ, Hillman SJ, van der Linden ML, Hazlewood ME, Robb JE. The mid-point of passive hip rotation range is an indicator of hip rotation in gait in cerebral palsy. Gait Posture. 2003;17: 88–91. doi: 10.1016/s0966-6362(02)00056-5 [DOI] [PubMed] [Google Scholar]
39.Keenan WN, Rodda J, Wolfe R, Roberts S, Borton DC, Graham HK. The static examination of children and young adults with cerebral palsy in the gait analysis laboratory: technique and observer agreement. Journal of Pediatric Orthopedics Part B. 2004;13: 1–8. doi: 10.1097/00009957-200401000-00001 [DOI] [PubMed] [Google Scholar]
40.Novacheck TF, Trost JP, Sohrweide S. Examination of the Child with Cerebral Palsy. Orthopedic Clinics of North America. 2010;41: 469–488. doi: 10.1016/j.ocl.2010.07.001 [DOI] [PubMed] [Google Scholar]
41.Mudge AJ, Bau KV, Purcell LN, Wu JC, Axt MW, Selber P, et al. Normative reference values for lower limb joint range, bone torsion, and alignment in children aged 4–16 years. J Pediatr Orthop B. 2014;23: 15–25. doi: 10.1097/BPB.0b013e328364220a [DOI] [PubMed] [Google Scholar]
42.Schwartz MH, Rozumalski A. The Gait Deviation Index: a new comprehensive index of gait pathology. Gait Posture. 2008;28: 351–357. doi: 10.1016/j.gaitpost.2008.05.001 [DOI] [PubMed] [Google Scholar]
43.Steele KM, Rozumalski A, Schwartz MH. Muscle synergies and complexity of neuromuscular control during gait in cerebral palsy. Developmental Medicine & Child Neurology. 2015;57: 1176–1182. doi: 10.1111/dmcn.12826 [DOI] [PMC free article] [PubMed] [Google Scholar]
44.Baba K, Shibata R, Sibuya M. Partial Correlation and Conditional Correlation as Measures of Conditional Independence. Australian & New Zealand Journal of Statistics. 2004;46: 657–664. doi: 10.1111/j.1467-842X.2004.00360.x [DOI] [Google Scholar]
45.Gelman A, Hill J, Vehtari A. Section 16.4. Regression and Other Stories. Cambridge: Cambridge University Press; 2020. doi: 10.1017/9781139161879 [DOI] [Google Scholar]
46.Noble JJ, Gough M, Shortland AP. Selective motor control and gross motor function in bilateral spastic cerebral palsy. Developmental Medicine and Child Neurology. 2019;61: 57–61. doi: 10.1111/dmcn.14024 [DOI] [PubMed] [Google Scholar]
47.Schwartz MH, Rozumalski A, Steele KM. Dynamic motor control is associated with treatment outcomes for children with cerebral palsy. Developmental Medicine & Child Neurology. 2016. [cited 25 Apr 2016]. doi: 10.1111/dmcn.13126 [DOI] [PMC free article] [PubMed] [Google Scholar]
48.Choi JY, Kim SK, Park ES. The Effect of Botulinum Toxin Injections on Gross Motor Function for Lower Limb Spasticity in Children with Cerebral Palsy. Toxins. 2019;11. doi: 10.3390/toxins11110651 [DOI] [PMC free article] [PubMed] [Google Scholar]
49.Pin T, McCartney L, Lewis J, Waugh M. Use of intrathecal baclofen therapy in ambulant children and adolescents with spasticity and dystonia of cerebral origin: a systematic review. In: Developmental medicine and child neurology [Internet]. Dev Med Child Neurol; Oct 2011 [cited 14 Oct 2020]. doi: 10.1111/j.1469-8749.2011.03992.x [DOI] [PubMed]
50.Hanna SE, Bartlett DJ, Rivard LM, Russell DJ. Reference curves for the Gross Motor Function Measure: percentiles for clinical description and tracking over time among children with cerebral palsy. Phys Ther. 2008;88: 596–607. doi: 10.2522/ptj.20070314 [DOI] [PMC free article] [PubMed] [Google Scholar]
51.Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Developmental Medicine and Child Neurology. 1997;39: 214–223. doi: 10.1111/j.1469-8749.1997.tb07414.x [DOI] [PubMed] [Google Scholar]
52.Rajagopal A, Kidziński Ł, McGlaughlin AS, Hicks JL, Delp SL, Schwartz MH. Estimating the effect size of surgery to improve walking in children with cerebral palsy from retrospective observational clinical data. Scientific Reports. 2018;8: 16344. doi: 10.1038/s41598-018-33962-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
53.Wang H-Y, Yang YH. Evaluating the responsiveness of 2 versions of the gross motor function measure for children with cerebral palsy. Arch Phys Med Rehabil. 2006;87: 51–56. doi: 10.1016/j.apmr.2005.08.117 [DOI] [PubMed] [Google Scholar]
54.Luz CL, Moura MCDS de, Becker KK, Teixeira RAA, Voos MC, Hasue RH. The relationship between motor function, cognition, independence and quality of life in myelomeningocele patients. Arq Neuropsiquiatr. 2017;75: 509–514. doi: 10.1590/0004-282X20170088 [DOI] [PubMed] [Google Scholar]

PLoS One. doi: 10.1371/journal.pone.0270121.r001

Decision Letter 0

YunJu Lee

28 Feb 2022

PONE-D-21-29034

Causal factors affecting gross motor function in children diagnosed with cerebral palsy

PLOS ONE

Dear Dr. MacWilliams,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Apr 07 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

YunJu Lee

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/fileid=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf".

2. As you are reporting a retrospective study of medical records, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.

3. "We noted in your submission details that a portion of your manuscript may have been presented or published elsewhere. [DETAILS AS NEEDED] Please clarify whether this [conference proceeding or publication] was peer-reviewed and formally published. If this work was previously peer-reviewed and published, in the cover letter please provide the reason that this work does not constitute dual publication and should be included in the current manuscript.

4. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for asking me to review this interesting paper I like the idea behind this article. CP is a complex condition and there is a place for more complex analysis when evaluating treatments and training. The authors have done a great job in analysing and presenting the data and I believe that this paper could be important for researchers and clinicians working with people with cerebral palsy.

I want to start by pointing out that I am a clinician first and not confident yet in my role as a reviewer. My knowledge of the advanced statistical analysis method in this paper is limited. I have therefore asked my co-writer and docent Wim Grooten for help in this regard. We have also discussed other aspects of the manuscript, but all information was handled confidentially, and no information has been spread elsewhere. After discussing with him, we agreed that the statistical analysis was sound and the results interesting.

With that said, I have some minor questions and concerns after reading the manuscript.

Aim:

The aim of the study has not explicitly been formulated, not in the end of the introduction or in the abstract. I think to increase the readability of the paper, the authors could formulate their research questions and purpose more clearly on these places.

Introduction:

You use the words “effectively improve function” (in the first paragraph of the introduction) and “alter gross motor function substantially” (in the last paragraph on page 21). This is a little confusing for the reader and could use some clarification, what do you mean when you say effectively and substantially?

Results

On page 17, the second paragraph starts a bit strange. Does all the text belong to figure 2 or is it main text in the result section? The bold writing indicates that it belongs to the figure, but it is a little unclear.

Results/ discussion:

In the first paragraph on page 20 you state that contractures had a small effect on GMFM- 66. GMFM- 66 measures peak performance for the day and time when it was performed and does not evaluate quality of movement or endurance. So maybe contractures have little effect on GMFM- 66, but what about in everyday life or during walks? Do they have a bigger influence on gross motor function then?

Second paragraph on page 20 you state that “factors explaining 75% of gross motor function can be measured during routine gait analysis”. This might be true for clinicians that perform advanced gait analyses, but is this statement valid for all kinds of gait analyses? Furthermore, do you mean 75% of gross motor function or 75% of gross motor function measured with GMFM-66? If I understand you correctly it is 75% of the factors reflected in the GMFM- 66.

It was interesting to read that selective and dynamic motor control had the largest effect sizes in the model. I think that it is hard to differentiate gross motor control/ function from selective and dynamic motor control; if one of them improves, the others are bound to be affected. For what is gross motor skills if not variants of selective and dynamic movements? This could explain part of the result and could be worth mentioning in the discussion section.

On page 21 and 22 you discuss the influence of age on the results. The last sentence on page 21 I agree with but the start on page 22 is somewhat confusing for me. The sentence when you introduce GMFCS is hard to read because of the parentheses, I realise they must be there but maybe try rephrasing it. Overall, the first paragraph on page 22 is a bit hard to understand. If the reader is familiar with the gross motor curves and their plateaus it makes it a bit clearer, but it is still hard to follow. So maybe look it over one more time to see if it can be made more understandable.

I think the discussion is somewhat long, especially the part with the heading “summary”. This “summary” of two pages is, in my regard, not a summary, but rather a methodological consideration. However, most of topics are interesting but could be condensed under a different heading. Also, could the authors provide a “conclusion” in the end of the discussion? The conclusion available in the abstract could be used as a starting point here and, if possible, should reflect both the implication for clinical work and future research.

Reviewer #2: Thank you for submitting this manuscript aiming to overcome the bottleneck in enhance motor function in children with cerebral palsy. This is an important start for clinical practitioners to re-consider and implement efficacious intervention to support this population. I still have few suggestions and questions regarding the content and result interpretation.

1. The proposed causal model was based on clinical speculations regarding relationship between impairments and associated motor function and is somehow supported by the result of linear models. However, consider the nature of retrospective approach with cross-sectional data set, it still needs to be more conservative in claiming a cause-and-effect relationship, which may be more complicated than it is interpreted in the present manuscript. I still suggested to tone down the conclusions while adding more discussion regarding the potential bidirectional or mediation effect.

- For example, whether spasticity might be the mediating variables between selective motor control and functional outcome although the effect size of spasticity is small. This may also lead to a different judgement, together with the current evidence, on whether common tone management approaches are still with their values.

- “The effect of age on gross motor function is accounted for both directly, reflecting motor learning associated with practice, and indirectly, reflecting neuromaturation and growth.” This is an example of not knowing the cause-and-effect relationship or uncertain direction of the influence of one factor on the other. For example, age can have both the positive and negative impact on gait and functional performance. The negative influence may come from increased body weight and severer secondary impairments such as contracture. The other example is bony torsion, which may be worsen by on developing bone with walking.

2. Introduction: I would also suggest introducing CP (the first few sentences of current 2nd paragraph) before getting into more details regarding the evidence of current intervention effects. Please also add more information regarding the effect in treating different impairments in children with CP in the introduction or discussion

3. Introduction: Functional training and environmental modifications have showed stronger evidence in improving motor function in children with CP. However, there is insufficient review on relevant evidence in the introduction. Thus, it is suggested to add this information and discuss how it may help to support your findings or vice versa

4. Introduction: The following sentence is suggested to be removed

“ This assumption is entirely plausible. In fact, we demonstrate below that strength is an important causal factor, though with a substantially smaller impact than bivariate estimates would suggest. “

5. Method: Are there references to support the proposed causal model? There is no reference in the whole section of “Causal model”

6. Method: Although addressed in the discussion, I still have concerned toward averaging bilateral data in children with unilateral involvement. The effect of independent variables may be offset with it. This may be worth to first test which side of the data shows stronger impact on the functional outcome or the difference between affected and non-affected side plays a better role. In addition, what is the proportion of children with hemiplegia?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Emma Nylén, Registered Physiotherapist, Master of Science

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PLOS one review_2022.pdf

Click here for additional data file.^{(109.2KB, pdf)}

PLoS One. 2022 Jul 18;17(7):e0270121. doi: 10.1371/journal.pone.0270121.r002

Author response to Decision Letter 0

18 Apr 2022

These are contained in a separate document but here they are ...

Response to Reviewers:

We would like to thank the reviewers for their comments, which we address point by point below. Additions or changes to the text from the original manuscript are recorded per journal instructions using the track changes tool in Word.

Reviewer’s Comments:

Reviewer 1

Thank you for asking me to review this interesting paper I like the idea behind this article. CP is a complex condition and there is a place for more complex analysis when evaluating treatments and training. The authors have done a great job in analysing and presenting the data and I believe that this paper could be important for researchers and clinicians working with people with cerebral palsy.

With that said, I have some minor questions and concerns after reading the manuscript.

Aim:

Response: Aim and purpose are given in the abstract (Aim paragraph), and at the end of the introduction: “In this study, we hypothesize and test a causal model for GMFM-66 that examines the influence of key neurological and orthopedic impairments commonly measured during a gait analysis visit, which includes a comprehensive physical exam, standard functional measures, and 3D kinematics and electromyography collected during walking.”

Revision: Altered the aim sentence at the end of the introduction to read: “The aim of this study is to hypothesize and test a causal model for GMFM-66 that examines the influence of key neurological and orthopedic impairments commonly measured during a gait analysis visit, which includes a comprehensive physical exam, standard functional measures, and 3D kinematics and electromyography collected during walking.”

Introduction:

Response: Both adjectives were meant to describe that only small responses occurred or would be expected.

Revision: In the first instance we remove “effectively” so that the sentence now reads: “There is little evidence that common treatments for the CP child improve function.” In the second instance we have not revised as we state first that Age did not have a significant effect in the model. With maturation it is reasonable to expect some improvement in function, at least in very young children, as motor learning increases. Yet the model did not find a significant effect of Age. This is why we state: “…age alone is not expected to alter gross motor function substantially.” Introduction has been expanded and reorganized.

Results

Response: All text does belong to Figure 2. Hopefully with the manuscript properly laid out this will alleviate the confusion. For the revision we have inserted labels to mark these caption paragraphs as well as line separators to isolate the caption text.

Results/ discussion:

Response: We only measure function via GMFM-66 and so we cannot extend these results to other measures of function. The influence of contractures on gait as measured by the gait deviation index is accounted for as shown in Figure 1.

Response: The reference to routine gait was meant to reflect our own practice, which in our experience as an accredited laboratory, is generally in line with other accredited labs. Gross motor function measures here always refer the GMFM-66 measure. This is further clarified in the Methods: “Model inputs are limited to those variables routinely collected during a motion analysis study for children with spastic CP at one center.”

Revision: Altered the referenced sentence to now read: “Second, the results indicate that 75% of gross motor function as measured by the GMFM-66 can be accounted for by measures commonly recorded during clinical gait analysis.”

Response: This is precisely true, but equally true are the complex relationships that exist between motor control and function as illustrated in Figure 1. As shown in Figure 2, simple bivariate relationships to GMFM-66 would overestimate motor control measure contributions by more than double what we have found in the proposed model. Finally, perhaps contradicting somewhat the comment above, we found these two measures actually have a large degree of independency as we explain:

“Dynamic motor control, as measured by Walk-DMC (39), also had a large effect size, even after controlling for selective voluntary motor control. This suggests that the neurological pathways employed during quasi-static tasks and those used during gait are not the same, and both are important for function. In our proposed model, selective and dynamic motor control deficits share a common cause and are hence correlated (Walk-DMC ← Injury → SCALE).”

Revision: Moved the citation so that parentheses are not juxtaposed.

Revision: We have rearranged the Summary section to include an ending Conclusions paragraph.

Response: Regarding spasticity both direct and indirect (mediating) effects are small, so we can confidently say that alteration in spasticity will not have large effect on GMFM-66. This has been supported in a recent publication where subjects matched at an early baseline age and studied as adults showed equivalent changes in GMFM-66 independent of spasticity reduction status. We agree with the points about directionality of factors however this is inherent in the data (some positive changes, some negative changes) and the cause-effect considerations as shown in Figure 1. For example age is causally related to all contractures (likely that contractures increase with age as noted) and is causally related to GMFM-66 (we know that for age <8 GMFM-66 should improve with age). Finally, we have tried to be extremely careful and forward about the limitations of the model including:

“A causal diagram is a hypothesis. Since counterfactual observations (e.g., a clone of a specific child with one clinical parameter altered) do not exist, causal diagrams can never be fully proven or falsified.”

“As data were limited to variables retrospectively collected from standard gait analysis studies at a single center, some potentially important factors were omitted.“

“This study should be viewed as a starting point, and not as a definitive model of causality and function in children with CP. We proposed a model limited to data available from existing motion analysis studies …”

“While our proposed model is imperfect, it is transparent and explicit. Additional work is needed to discover more complete causal models and to devise experiments that confirm or refute the results of these models.”

Revision: Added the following sentence to the limitations: “Finally, this is a retrospective analysis of cross sectional data and all causal relationships are hypothesized based on past observations or logistically based assumptions.”

Revision: Paragraphs added to introduction to expand definition and incidence of CP and treatment modalities. Introduction reorganized to include further information of common treatment modalities.

Response: It is of course difficult to give a comprehensive review of the literature regarding treatment modalities and their efficacy in CP. We have attempted to limit the discussion to those studies that have directly measured GMFM-66, the outcome variable that was studied in the model.

Revision: We have reorganized and added information to the introduction, however, we have been unable to find any evidence that functional training and environmental modifications have shown long-term improvements in GMFM-66. We did find one additional citation (Ketelaar et al., 2001) regarding short-term improvement and have added that.

4. Introduction: The following sentence is suggested to be removed

Response: The authors feel that this is a key point to justify and promote the use of explicit causal inferences and modeling. Thus we have retained some of this argument.

Revision: The first sentence has been deleted and the second modified.

5. Method: Are there references to support the proposed causal model? There is no reference in the whole section of “Causal model”

Response: Two citations were included to support this section:

Pearl J. Causal diagrams for empirical research. Biometrika. 1995 Dec 1;82(4):669–88.

Textor J, van der Zander B, Gilthorpe MS, Liśkiewicz M, Ellison GT. Robust causal inference using directed acyclic graphs: the R package ‘dagitty.’ Int J Epidemiol. 2016 Dec 1;45(6):1887–94.

Revision: A more general citation of causal modelling has been added to support this paragraph: Pearl J. Causality [Internet]. 2nd ed. Cambridge: Cambridge University Press; 2009

Response: Early work not reported here compared results using:

1) A random side of individuals with bilateral CP and the hemiparetic side of individuals with unilateral

2) Side with best dynamic motor control of individuals with bilateral CP and the hemiparetic side of individuals with unilateral

3) Side with worst dynamic motor control of individuals with bilateral CP and the hemiparetic side of individuals with unilateral

4) Average used here

There was very little difference in the results based on these choices and logistically, the average values made the most sense to us given the nature of the specific motor tasks used for GMFM-66. The number of hemiplegic individuals is included in Table 2. There were 118 of the 300 or 39%.

Attachment

Submitted filename: Response to Reviewers.docx

Click here for additional data file.^{(22.3KB, docx)}

PLoS One. doi: 10.1371/journal.pone.0270121.r003

Decision Letter 1

YunJu Lee

6 Jun 2022

Causal factors affecting gross motor function in children diagnosed with cerebral palsy

PONE-D-21-29034R1

Dear Dr. MacWilliams,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

YunJu Lee

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

Reviewer #1: Yes

**********

6. Review Comments to the Author

Reviewer #1: The authors have responded to the comments. And I feel satisfied with the answers and revisions.

As stated before my knowledge of advanced statistical analysis is limited therefore I can not give a more sound answer to that question.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

PLoS One. doi: 10.1371/journal.pone.0270121.r004

Acceptance letter

YunJu Lee

7 Jul 2022

PONE-D-21-29034R1

Causal factors affecting gross motor function in children diagnosed with cerebral palsy

Dear Dr. MacWilliams:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. YunJu Lee

Academic Editor

PLOS ONE

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 Data

(CSV)

Click here for additional data file.^{(42.7KB, csv)}

Attachment

Submitted filename: PLOS one review_2022.pdf

Click here for additional data file.^{(109.2KB, pdf)}

Attachment

Submitted filename: Response to Reviewers.docx

Click here for additional data file.^{(22.3KB, docx)}

Data Availability Statement

All relevant data are within the manuscript and its Supporting Information files.

[pone.0270121.ref001] 1.Kerr C, McDowell B, McDonough S. The relationship between gross motor function and participation restriction in children with cerebral palsy: an exploratory analysis. Child: Care, Health and Development. 2007;33: 22–27. doi: 10.1111/j.1365-2214.2006.00634.x [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref002] 2.Lee B-H. Relationship between gross motor function and the function, activity and participation components of the International Classification of Functioning in children with spastic cerebral palsy. Journal of Physical Therapy Science. 2017;29: 1732–1736. doi: 10.1589/jpts.29.1732 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0270121.ref003] 3.Palisano RJ, Kang L-J, Chiarello LA, Orlin M, Oeffinger D, Maggs J. Social and community participation of children and youth with cerebral palsy is associated with age and gross motor function classification. Physical Therapy. 2009;89: 1304–1314. doi: 10.2522/ptj.20090162 [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref004] 4.Rosenbaum PL, Walter SD, Hanna SE, Palisano RJ, Russell DJ, Raina P, et al. Prognosis for gross motor function in cerebral palsy: creation of motor development curves. JAMA. 2002;288: 1357–1363. doi: 10.1001/jama.288.11.1357 [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref005] 5.Colver A, Fairhurst C, Pharoah POD. Cerebral palsy. Lancet. 2013. doi: 10.1016/S0140-6736(13)61835-8 [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref006] 6.Russell DJ, Rosenbaum PL, Cadman DT, Gowland C, Hardy S, Jarvis S. The gross motor function measure: a means to evaluate the effects of physical therapy. Developmental Medicine and Child Neurology. 1989;31: 341–352. doi: 10.1111/j.1469-8749.1989.tb04003.x [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref007] 7.Russell DJ, Avery LM, Rosenbaum PL, Raina PS, Walter SD, Palisano RJ. Improved scaling of the gross motor function measure for children with cerebral palsy: evidence of reliability and validity. Phys Ther. 2000;80: 873–885. [PubMed] [Google Scholar]

[pone.0270121.ref008] 8.Ostensjø S, Carlberg EB, Vøllestad NK. Motor impairments in young children with cerebral palsy: relationship to gross motor function and everyday activities. Dev Med Child Neurol. 2004;46: 580–589. doi: 10.1017/s0012162204000994 [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref009] 9.Smits D-W, Gorter JW, Ketelaar M, Van Schie PE, Dallmeijer AJ, Lindeman E, et al. Relationship between gross motor capacity and daily-life mobility in children with cerebral palsy. Dev Med Child Neurol. 2010;52: e60–66. doi: 10.1111/j.1469-8749.2009.03525.x [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref010] 10.Novak I, McIntyre S, Morgan C, Campbell L, Dark L, Morton N, et al. A systematic review of interventions for children with cerebral palsy: state of the evidence. Dev Med Child Neurol. 2013;55: 885–910. doi: 10.1111/dmcn.12246 [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref011] 11.Thomason P, Baker R, Dodd K, Taylor N, Selber P, Wolfe R, et al. Single-event multilevel surgery in children with spastic diplegia: a pilot randomized controlled trial. The Journal of Bone and Joint Surgery American Volume. 2011;93: 451–460. doi: 10.2106/JBJS.J.00410 [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref012] 12.McGinley JL, Dobson F, Ganeshalingam R, Shore BJ, Rutz E, Graham HK. Single-event multilevel surgery for children with cerebral palsy: a systematic review. Developmental Medicine and Child Neurology. 2012;54: 117–128. doi: 10.1111/j.1469-8749.2011.04143.x [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref013] 13.Chang C-H, Chen Y-Y, Yeh K-K, Chen C-L. Gross motor function change after multilevel soft tissue release in children with cerebral palsy. Biomedical Journal. 2017;40: 163–168. doi: 10.1016/j.bj.2016.12.003 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0270121.ref014] 14.Bolster EAM, van Schie PEM, Becher JG, van Ouwerkerk WJR, Strijers RLM, Vermeulen RJ. Long-term effect of selective dorsal rhizotomy on gross motor function in ambulant children with spastic bilateral cerebral palsy, compared with reference centiles. Developmental Medicine and Child Neurology. 2013;55: 610–616. doi: 10.1111/dmcn.12148 [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref015] 15.van Schie PEM, Schothorst M, Dallmeijer AJ, Vermeulen RJ, van Ouwerkerk WJR, Strijers RLM, et al. Short- and long-term effects of selective dorsal rhizotomy on gross motor function in ambulatory children with spastic diplegia. Journal of Neurosurgery Pediatrics. 2011;7: 557–562. doi: 10.3171/2011.2.PEDS10452 [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref016] 16.Tedroff K, Hägglund G, Miller F. Long-term effects of selective dorsal rhizotomy in children with cerebral palsy: a systematic review. Developmental Medicine and Child Neurology. 2020;62: 554–562. doi: 10.1111/dmcn.14320 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0270121.ref017] 17.Tedroff K, Löwing K, Åström E. A prospective cohort study investigating gross motor function, pain, and health-related quality of life 17 years after selective dorsal rhizotomy in cerebral palsy. Developmental Medicine and Child Neurology. 2015;57: 484–490. doi: 10.1111/dmcn.12665 [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref018] 18.McLaughlin J, Bjornson K, Temkin N, Steinbok P, Wright V, Reiner A, et al. Selective dorsal rhizotomy: meta-analysis of three randomized controlled trials. Developmental Medicine and Child Neurology. 2002;44: 17–25. doi: 10.1017/s0012162201001608 [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref019] 19.MacWilliams BA, McMulkin ML, Duffy EA, Munger ME, Chen BP-J, Novacheck TF, et al. Long-term effects of spasticity treatment, including selective dorsal rhizotomy, for individuals with cerebral palsy. Developmental Medicine & Child Neurology. 2021; n/a. doi: 10.1111/dmcn.15075 [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref020] 20.Tsorlakis N, Evaggelinou C, Grouios G, Tsorbatzoudis C. Effect of intensive neurodevelopmental treatment in gross motor function of children with cerebral palsy. Developmental Medicine and Child Neurology. 2004;46: 740–745. doi: 10.1017/s0012162204001276 [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref021] 21.İçağasıoğlu A, Mesci E, Yumusakhuylu Y, Turgut ST, Murat S. Rehabilitation outcomes in children with cerebral palsy during a 2 year period. Journal of Physical Therapy Science. 2015;27: 3211–3214. doi: 10.1589/jpts.27.3211 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0270121.ref022] 22.Park E-Y. Effect of physical therapy frequency on gross motor function in children with cerebral palsy. Journal of Physical Therapy Science. 2016;28: 1888–1891. doi: 10.1589/jpts.28.1888 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0270121.ref023] 23.Kramer JF, MacPhail AH. Relationships Among Measures of Walking Efficiency, Gross Motor Ability, and Isokinetic Strength In Adolescents With Cerebral Palsy. Pediatric Physical Therapy. 1994;6: 3–9. [Google Scholar]

[pone.0270121.ref024] 24.Damiano DL, Martellotta TL, Sullivan DJ, Granata KP, Abel MF. Muscle force production and functional performance in spastic cerebral palsy: relationship of cocontraction. Arch Phys Med Rehabil. 2000;81: 895–900. doi: 10.1053/apmr.2000.5579 [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref025] 25.Shin HI, Sung KH, Chung CY, Lee KM, Lee SY, Lee IH, et al. Relationships between Isometric Muscle Strength, Gait Parameters, and Gross Motor Function Measure in Patients with Cerebral Palsy. Yonsei Med J. 2016;57: 217–224. doi: 10.3349/ymj.2016.57.1.217 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0270121.ref026] 26.Ross SA, Engsberg JR. Relationships Between Spasticity, Strength, Gait, and the GMFM-66 in Persons With Spastic Diplegia Cerebral Palsy. Archives of Physical Medicine and Rehabilitation. 2007;88: 1114–1120. doi: 10.1016/j.apmr.2007.06.011 [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref027] 27.Eek MN, Beckung E. Walking ability is related to muscle strength in children with cerebral palsy. Gait Posture. 2008;28: 366–371. doi: 10.1016/j.gaitpost.2008.05.004 [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref028] 28.Pearl J. Causal diagrams for empirical research. Biometrika. 1995;82: 669–688. doi: 10.1093/biomet/82.4.669 [DOI] [Google Scholar]

[pone.0270121.ref029] 29.Fairchild AJ, MacKinnon DP, Taborga MP, Taylor AB. R2 effect-size measures for mediation analysis. Behav Res Methods. 2009;41: 486–498. doi: 10.3758/BRM.41.2.486 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0270121.ref030] 30.Kim WH, Park EY. Causal relation between spasticity, strength, gross motor function, and functional outcome in children with cerebral palsy: a path analysis. Developmental Medicine and Child Neurology. 2011;53: 68–73. doi: 10.1111/j.1469-8749.2010.03777.x [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref031] 31.Textor J, van der Zander B, Gilthorpe MS, Liśkiewicz M, Ellison GT. Robust causal inference using directed acyclic graphs: the R package ‘dagitty.’ Int J Epidemiol. 2016;45: 1887–1894. doi: 10.1093/ije/dyw341 [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref032] 32.Pearl J. Causality. 2nd ed. Cambridge: Cambridge University Press; 2009. doi: 10.1017/CBO9780511803161 [DOI] [Google Scholar]

[pone.0270121.ref033] 33.Munger ME, Chen BP-J, MacWilliams BA, McMulkin ML, Schwartz MH. Comparing the effects of two spasticity management strategies on the long-term outcomes of individuals with bilateral spastic cerebral palsy: a multicentre cohort study protocol. BMJ open. 2019;9: e027486. doi: 10.1136/bmjopen-2018-027486 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0270121.ref034] 34.Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Physical Therapy. 1987;67: 206–207. doi: 10.1093/ptj/67.2.206 [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref035] 35.Kendall FP. Muscles: Testing and function with posture and pain. Baltimore, MD: Lippincott Williams & Wilkins; 2005. [Google Scholar]

[pone.0270121.ref036] 36.van der Ploeg RJ, Oosterhuis HJ. The “make/break test” as a diagnostic tool in functional weakness. Journal of Neurology, Neurosurgery, and Psychiatry. 1991;54: 248–251. doi: 10.1136/jnnp.54.3.248 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0270121.ref037] 37.Fowler EG, Staudt LA, Greenberg MB, Oppenheim WL. Selective Control Assessment of the Lower Extremity (SCALE): development, validation, and interrater reliability of a clinical tool for patients with cerebral palsy. Dev Med Child Neurol. 2009;51: 607–614. doi: 10.1111/j.1469-8749.2008.03186.x [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref038] 38.Kerr AM, Kirtley SJ, Hillman SJ, van der Linden ML, Hazlewood ME, Robb JE. The mid-point of passive hip rotation range is an indicator of hip rotation in gait in cerebral palsy. Gait Posture. 2003;17: 88–91. doi: 10.1016/s0966-6362(02)00056-5 [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref039] 39.Keenan WN, Rodda J, Wolfe R, Roberts S, Borton DC, Graham HK. The static examination of children and young adults with cerebral palsy in the gait analysis laboratory: technique and observer agreement. Journal of Pediatric Orthopedics Part B. 2004;13: 1–8. doi: 10.1097/00009957-200401000-00001 [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref040] 40.Novacheck TF, Trost JP, Sohrweide S. Examination of the Child with Cerebral Palsy. Orthopedic Clinics of North America. 2010;41: 469–488. doi: 10.1016/j.ocl.2010.07.001 [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref041] 41.Mudge AJ, Bau KV, Purcell LN, Wu JC, Axt MW, Selber P, et al. Normative reference values for lower limb joint range, bone torsion, and alignment in children aged 4–16 years. J Pediatr Orthop B. 2014;23: 15–25. doi: 10.1097/BPB.0b013e328364220a [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref042] 42.Schwartz MH, Rozumalski A. The Gait Deviation Index: a new comprehensive index of gait pathology. Gait Posture. 2008;28: 351–357. doi: 10.1016/j.gaitpost.2008.05.001 [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref043] 43.Steele KM, Rozumalski A, Schwartz MH. Muscle synergies and complexity of neuromuscular control during gait in cerebral palsy. Developmental Medicine & Child Neurology. 2015;57: 1176–1182. doi: 10.1111/dmcn.12826 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0270121.ref044] 44.Baba K, Shibata R, Sibuya M. Partial Correlation and Conditional Correlation as Measures of Conditional Independence. Australian & New Zealand Journal of Statistics. 2004;46: 657–664. doi: 10.1111/j.1467-842X.2004.00360.x [DOI] [Google Scholar]

[pone.0270121.ref045] 45.Gelman A, Hill J, Vehtari A. Section 16.4. Regression and Other Stories. Cambridge: Cambridge University Press; 2020. doi: 10.1017/9781139161879 [DOI] [Google Scholar]

[pone.0270121.ref046] 46.Noble JJ, Gough M, Shortland AP. Selective motor control and gross motor function in bilateral spastic cerebral palsy. Developmental Medicine and Child Neurology. 2019;61: 57–61. doi: 10.1111/dmcn.14024 [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref047] 47.Schwartz MH, Rozumalski A, Steele KM. Dynamic motor control is associated with treatment outcomes for children with cerebral palsy. Developmental Medicine & Child Neurology. 2016. [cited 25 Apr 2016]. doi: 10.1111/dmcn.13126 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0270121.ref048] 48.Choi JY, Kim SK, Park ES. The Effect of Botulinum Toxin Injections on Gross Motor Function for Lower Limb Spasticity in Children with Cerebral Palsy. Toxins. 2019;11. doi: 10.3390/toxins11110651 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0270121.ref049] 49.Pin T, McCartney L, Lewis J, Waugh M. Use of intrathecal baclofen therapy in ambulant children and adolescents with spasticity and dystonia of cerebral origin: a systematic review. In: Developmental medicine and child neurology [Internet]. Dev Med Child Neurol; Oct 2011 [cited 14 Oct 2020]. doi: 10.1111/j.1469-8749.2011.03992.x [DOI] [PubMed]

[pone.0270121.ref050] 50.Hanna SE, Bartlett DJ, Rivard LM, Russell DJ. Reference curves for the Gross Motor Function Measure: percentiles for clinical description and tracking over time among children with cerebral palsy. Phys Ther. 2008;88: 596–607. doi: 10.2522/ptj.20070314 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0270121.ref051] 51.Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Developmental Medicine and Child Neurology. 1997;39: 214–223. doi: 10.1111/j.1469-8749.1997.tb07414.x [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref052] 52.Rajagopal A, Kidziński Ł, McGlaughlin AS, Hicks JL, Delp SL, Schwartz MH. Estimating the effect size of surgery to improve walking in children with cerebral palsy from retrospective observational clinical data. Scientific Reports. 2018;8: 16344. doi: 10.1038/s41598-018-33962-2 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0270121.ref053] 53.Wang H-Y, Yang YH. Evaluating the responsiveness of 2 versions of the gross motor function measure for children with cerebral palsy. Arch Phys Med Rehabil. 2006;87: 51–56. doi: 10.1016/j.apmr.2005.08.117 [DOI] [PubMed] [Google Scholar]

[pone.0270121.ref054] 54.Luz CL, Moura MCDS de, Becker KK, Teixeira RAA, Voos MC, Hasue RH. The relationship between motor function, cognition, independence and quality of life in myelomeningocele patients. Arq Neuropsiquiatr. 2017;75: 509–514. doi: 10.1590/0004-282X20170088 [DOI] [PubMed] [Google Scholar]

PERMALINK

Causal factors affecting gross motor function in children diagnosed with cerebral palsy

Bruce A MacWilliams

Sarada Prasad

Amy L Shuckra

Michael H Schwartz

Roles

Abstract

Background

Aim

Method

Results

Interpretation

Introduction

Gross motor function in cerebral palsy

Association studies of function

Explicit causal approach

Methods

Causal model

Fig 1. Directed acyclic graph (DAG).

Table 1. Causal model.

Study data

Body functions and structure

Activity and participation

Personal factors

Health condition

Analysis

Results

Table 2. Participant characteristics.

Fig 2. Effect sizes.

Table 3. Predictive model coefficients.

Fig 3. Predicted vs. measured GMFM-66.

Discussion

Summary

Conclusions

Supporting information

Data Availability

Funding Statement

References

Decision Letter 0

YunJu Lee

Roles

Author response to Decision Letter 0

Decision Letter 1

YunJu Lee

Roles

Acceptance letter

YunJu Lee

Roles

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases